- Home
- TPB vs DNLI Comparison
TPB vs DNLI Comparison
Compare TPB & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPB | DNLI |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TPB | DNLI |
|---|---|---|
| Price | $127.94 | $19.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $115.00 | $30.82 |
| AVG Volume (30 Days) | 283.2K | ★ 1.8M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $435,716,000.00 | N/A |
| Revenue This Year | $29.51 | N/A |
| Revenue Next Year | $11.08 | $3,897.53 |
| P/E Ratio | $644.42 | ★ N/A |
| Revenue Growth | ★ 51.72 | N/A |
| 52 Week Low | $51.48 | $10.57 |
| 52 Week High | $130.69 | $23.77 |
Technical Indicators
Market Signals| Indicator | TPB | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 67.33 | 49.41 |
| Support Level | $123.75 | $19.76 |
| Resistance Level | $130.69 | $23.77 |
| Average True Range (ATR) | 4.04 | 1.38 |
| MACD | 0.11 | -0.22 |
| Stochastic Oscillator | 84.76 | 19.77 |
Price Performance
Historical ComparisonAbout TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.